Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8210920 | International Journal of Radiation Oncology*Biology*Physics | 2018 | 22 Pages |
Abstract
For patients with early-stage non-small cell lung cancer who are eligible for either treatment, better overall survival was seen after surgery compared with SABR. However, lung cancer-specific survival was similar for both treatments. Prospective clinical trials are preferred to propensity analyses in evaluating the nature of non-cancer-related death after SABR.
Related Topics
Physical Sciences and Engineering
Physics and Astronomy
Radiation
Authors
Hanbo MD, Joanna M. MD, R. Gabriel MLIS, Christopher D. MD, David A. MD, PhD, Suresh MRCP, PhD, Alexander V. MD, PhD,